Atossa Genetics, Inc. Announces Filing of S-1 Registration Statement
(firmenpresse) - SEATTLE, WA -- (Marketwire) -- 02/14/12 -- Atossa Genetics, Inc., a privately-held health care company focused on the prevention of breast cancer through the commercialization of diagnostic tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions, announced today that it has filed a registration statement on Form S-1 with the United States Securities and Exchange Commission (SEC) relating to a proposed initial public offering of 1,000,000 shares of its common stock. Dawson James Securities, Inc. is acting as sole book-running manager of the offering.
Proceeds from this offering will be used to expand the Company's cytology and molecular diagnostics laboratory, The National Reference Laboratory for Breast Health; fund the manufacture of MASCT System units; hire and train sales and marketing personnel for the ForeCYTE and ArgusCYTE Breast Health Tests; continue its research and development of the FullCYTE and NextCYTE Breast Health Tests; support the internal research and development of the Intraductal Treatment Research Program; and for general corporate purposes.
The offering will be made only by means of a prospectus. Once available, a preliminary prospectus may be obtained from Dawson James via telephone at 561-208-2939; email at , or standard mail at 925 S. Federal Highway, Suite 600, Boca Raton, FL 33432.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Atossa Genetics, Inc. is a privately held health care company based in Seattle, Washington, that provides a comprehensive set of innovative breast health evaluation products and services that provide accurate and actionable results for personalized cancer prevention and breast health. Atossa has established the National Reference Laboratory for Breast Health, a specially equipped, CLIA-registered laboratory located in Seattle that provides comprehensive test results to guide personalized breast cancer prevention and treatment solutions.
Corporate:
Steven C. Quay, M.D., Ph.D., FCAP (Corporate)
Chairman, President and CEO of Atossa Genetics and
Director of the National Reference Laboratory for Breast Health
206-325-6086
Investors and Media:
Matthew D. Haines
Managing Director
MBS Value Partners
212-710-9686
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 14.02.2012 - 14:15 Uhr
Sprache: Deutsch
News-ID 114414
Anzahl Zeichen: 0
contact information:
Town:
SEATTLE, WA
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 239 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Atossa Genetics, Inc. Announces Filing of S-1 Registration Statement"
steht unter der journalistisch-redaktionellen Verantwortung von
Atossa Genetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
